Literature DB >> 1592579

Apomorphine in malignant syndrome due to levodopa withdrawal.

U Bonuccelli1, P Piccini, G U Corsini, A Muratorio.   

Abstract

We report a case of neuroleptic malignant syndrome (NMS) following abrupt reduction of chronic levodopa treatment in a 71 year old female parkinsonian patient. The NMS resolved within 24 hours of the addition of apomorphine to levodopa therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592579     DOI: 10.1007/bf02226968

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  5 in total

1.  Fatal hyperpyrexia after withdrawal of levodopa.

Authors:  G P Sechi; F Tanda; R Mutani
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

Review 2.  Neuroleptic malignant syndrome. Review of response to therapy.

Authors:  M R Rosenberg; M Green
Journal:  Arch Intern Med       Date:  1989-09

3.  A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.

Authors:  J H Friedman; S S Feinberg; R G Feldman
Journal:  JAMA       Date:  1985-11-15       Impact factor: 56.272

4.  Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion.

Authors:  M E Rodriguez; M R Luquin; G Lera; G Delgado; J M Salazar; J A Obeso
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

5.  Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.

Authors:  L Figà-Talamanca; C Gualandi; L Di Meo; G Di Battista; G Neri; F Lo Russo
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

  5 in total
  2 in total

Review 1.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

Review 2.  The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Drugs R D       Date:  2018-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.